Search clinical trials for: BAY1841788 (darolutamide)

Total 78 results

UNICANCER
Bayer

Recruiting

ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)

Prostate Cancer Metastatic

Spain, France, Ireland, Belgium
Bayer

Completed

Drug-drug Interaction Study Using Rosuvastatin as a Breast Cancer Resistant Protein (Efflux Transporter), Organic Anion-transporting Polypeptide (OATP)1B1, and OATP1B3 (Uptake Transporters) Probe Substrate

Healthy Volunteers | Pharmacokinetics | Drug Interaction

Germany
University of Sydney
Memorial Sloan Kettering Cancer Center; Bayer; Canadian Cancer Trials Group; Australian... and other collaborators

Active, not recruiting

Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (DASL-HiCaP)

Prostate Cancer

United States, Canada, Australia, United Kingdom, New Zealand, Ireland
David VanderWeele

Terminated

Neoadjuvant Androgen Deprivation, Darolutamide, and Ipatasertib in Men With Localized, High Risk Prostate Cancer (ADDItion)

Castrate Resistant Prostate Cancer

United States
Canadian Cancer Trials Group
Canadian Cancer Clinical Trials Network; BC Cancer Foundation

Active, not recruiting

Prostate Cancer Biomarker Enrichment and Treatment Selection

Prostate Cancer

Canada
Jena University Hospital
Bayer

Recruiting

A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients (ARASAFE)

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Germany
Mamta Parikh
National Cancer Institute (NCI)

Recruiting

Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer

Stage IV Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Advanced Prostate Adenocarcinoma

United States
Yuhan Corporation

Completed

A Study to Evaluate the Effect of Sarpogrelate on Blood Hyperviscosity

Peripheral Artery Disease, PAD

Korea, Republic of
Latin American Cooperative Oncology Group
Bayer

Active, not recruiting

Extreme Bipolar Androgen Therapy With Darolutamide and Testosterone Cypionate in Patients With Metastatic Castration-Resistant Prostate Cancer (ExBAT Trial) (ExBAT)

Prostate Cancer

Brazil
AstraZeneca

Recruiting

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents (EvoPAR-PR01)

Metastatic Castration-Sensitive Prostate Cancer

United States, Canada, Spain, United Kingdom, Italy, Australia, Korea, Republic of, Belgium, Germany, Japan, Peru, France, China, India, Taiwan, Thailand, Austria, Brazil, Turkey, Malaysia, Finland, Netherlands, Chile, Hungary, Poland, Sw...
AstraZeneca
Bayer

Recruiting

Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer (PETRANHA)

Metastatic Prostate Cancer

Italy, United Kingdom, Australia, United States
Peking University Third Hospital
Bayer

Not yet recruiting

Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy in Prostate Cancer Patients With Lymph Node-positive After Radical Prostatectomy: A Prospective Observational Cohort Study

Prostate Cancer

China
Bayer

Completed

Inhibition of Ovulation and Pharmacokinetics of Transdermal Ethinylestradiol (EE) and Gestodene (GSD)

Contraception | Ovulation Inhibition

Germany
Praful Ravi, MB BCHir, MRCP
Eli Lilly and Company; Bayer

Active, not recruiting

Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer

Prostate Cancer | Metastatic Prostate Cancer | Non-metastatic Prostate Cancer

United States
Atish Choudhury, MD
Bayer; Pfizer; National Comprehensive Cancer Network; Sumitomo Pharma America,...

Not yet recruiting

Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED)

Prostate Cancer | Advanced Prostate Cancer | Hormone Sensitive Prostate Cancer

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study

Prostate Carcinoma

United States
Bayer
Parexel

Completed

Birth Control Patch Study

Contraception

Austria, Czech Republic, Netherlands
Medical University of Vienna
Lund University; Ziekenhuis Netwerk Antwerpen (ZNA); St. Antonius Hospital; Azienda... and other collaborators

Not yet recruiting

Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study (OLIGOMET)

Prostate Cancer | Prostate Cancer Metastatic | Oligometastasis | Prostate Neoplasm | Oligometastatic Disease | Prostate Cancer Metastatic to Bone
CellCentric Ltd.

Recruiting

Study to Evaluate CCS1477 in Advanced Tumours

Advanced Solid Tumors | Metastatic Breast Cancer | Non-small Cell Lung Cancer | Metastatic Castration-Resistant Prostate Cancer

United Kingdom, United States, Netherlands, France, Spain, Sweden
National Cancer Institute (NCI)

Recruiting

Testing the Anti-Cancer Drug Darolutamide in Patients With Testosterone-driven Salivary Gland Cancers

Recurrent Salivary Gland Carcinoma | Metastatic Salivary Gland Carcinoma | Unresectable Salivary Gland Carcinoma | Locally Advanced Salivary Gland Carcinoma

United States
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-resistant Prostate Neoplasms

United States, Australia
Bayer
Orion Corporation, Orion Pharma

Completed

Drug-drug Interaction (DDI) Study to Assess ODM-201 as a Victim of CYP3A4 Inhibition or Induction

Biological Availability

Germany
National Cancer Institute (NCI)
NRG Oncology

Suspended

Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors

Adult Ovarian Granulosa Cell Tumor

United States
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score

Prostate Adenocarcinoma

United States, Canada
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Recruiting

Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer

Neoadjuvant Therapy | High Risk Prostate Cancer | Locally Advanced Prostate Cancer | Intense Endocrine Therapy

China
Karolinska Institutet
The Swedish Research Council; AstraZeneca; Janssen Pharmaceutica N.V., Belgium; Kom Op Tegen Kanker and other collaborators

Recruiting

ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer (ProBio)

Metastatic Castration-resistant Prostate Cancer (mCRPC) | Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Sweden, Belgium, Switzerland, Norway
Mayo Clinic

Recruiting

Stereotactic Body Radiation Therapy Plus Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy for Treatment of Metastatic, Recurrent Hormone-Sensitive Prostate Cancer, DIVINE Trial (DIVINE)

Recurrent Prostate Cancer | Castration-resistant Prostate Cancer | Stage IVB Prostate Cancer AJCC v8 | Recurrent Castration-Sensitive Prostate Carcinoma

United States
OHSU Knight Cancer Institute
Oregon Health and Science University

Terminated

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Primary Myelofibrosis | Anemia | Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Anatomic Stage IV Breast Cancer AJCC v8 | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic... and other conditions

United States

Search clinical trials for: BAY1841788 (darolutamide)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Philippines

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations